The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 15, 2006

Filed:

Apr. 29, 2003
Applicants:

Kevin G. Pinney, Woodway, TX (US);

Vani P. Mocharla, Waco, TX (US);

Zhi Chen, Hamden, CT (US);

Charles M. Garner, Waco, TX (US);

Mallinath Hadimani, Waco, TX (US);

Raymond Kessler, Sugarland, TX (US);

James M. Dorsey, Durham, NC (US);

Klaus Edvardsen, Klampenborg, DK;

David J. Chaplin, Watlington, CA;

Joseph Prezioso, Boston, MA (US);

Usha Ghatak, Legal Representative, Salt Lake City, UT (US);

Inventors:

Kevin G. Pinney, Woodway, TX (US);

Vani P. Mocharla, Waco, TX (US);

Zhi Chen, Hamden, CT (US);

Charles M. Garner, Waco, TX (US);

Mallinath Hadimani, Waco, TX (US);

Raymond Kessler, Sugarland, TX (US);

James M. Dorsey, Durham, NC (US);

Klaus Edvardsen, Klampenborg, DK;

David J. Chaplin, Watlington, CA;

Joseph Prezioso, Boston, MA (US);

Usha Ghatak, legal representative, Salt Lake City, UT (US);

Assignees:

Oxigene, Inc., Watertown, MA (US);

Baylor University, Waco, TX (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/34 (2006.01); C07D 307/93 (2006.01);
U.S. Cl.
CPC ...
Abstract

A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.


Find Patent Forward Citations

Loading…